Victrelis

FDA approval came on May 13 and Merck & Co. Inc. (NYSE: MRK) will launch Victrelis this month, Deutsche Bank reports. “Labeling was generally very favorable for boceprevir, with no major exclusions or restrictions (other than for DDIs), and potential RGT options for most patients -- in our...